Skip to main content

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Watch or Listen to JNMT Podcast
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Follow SNMMI on Twitter
  • Subscribe to JNMT RSS feeds
OtherMessage from the President

Molecular Therapy: A New Focus for SNMMI-TS

Mark H. Crosthwaite
Journal of Nuclear Medicine Technology September 2019, 47 (3) 8A;
Mark H. Crosthwaite
SNMMI-TS President
CNMT, FSNMMI-TS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading
Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Mark H. Crosthwaite, CNMT, FSNMMI-TS

Over the last year I have had the opportunity to visit several chapters, and I would like to thank you all for your gracious hospitality. Thanks also to our friends in Australia, where I had the opportunity to attend the annual meeting of the Australia and New Zealand Society of Nuclear Medicine (ANZSNM). During these travels, I had the chance to share many ideas, have many enjoyable conversations, and attended numerous hours of continuing education. One prevailing theme echoed at every meeting: targeted therapy—or, to use the new buzzword, theranostics.

In the United States, most therapy lectures relate to the application of DOTATATE and its association with 68Ga and 177Lu. I heard about this at every chapter meeting. Exciting! However, when I was outside the country, I heard about targeted therapies extending far beyond 68Ga-DOTATATE and 177Lu-DOTATATE. For example, clinical research in Australia has “promising results” in the treatment of prostate cancer with the application of 177Lu-PMSA (1). In India there are ongoing clinical trials using α-particles, particularly with 225Ac-DOTATATE used to treat certain forms of neuroendocrine cancers (2). In Germany, 225Ac-PMSA is being used to treat prostate cancer (3).

When I asked our friends from down under, Is there an advantage of using α-therapy over β?, I was told that α-radiation is less toxic and does not travel very far, and the therapeutic dose is as much as 100-fold greater. Therefore, it appears we will be seeing more α-particle therapy in the near future.

How should SNMMI-TS respond to this? It appears that, once again, nuclear medicine has great opportunity to expand into new areas. Are we ready?

My focus as president will be to start a new Task Force on Molecular Therapy. James Crowley, CNMT, will be chairing the committee, and Seyed Mohammadi, CNMT, will be vice chair. The three main goals of the task force are:

  1. To keep radiotherapy in nuclear medicine, so nuclear medicine technologists will be the ones performing it.

  2. To keep nuclear medicine technologists informed with publications, including continuing education articles, and to develop a SNMMI Targeted Therapy portal.

  3. To promote radiotherapy to other physicians, patients, and the general public.

I leave you with one final thought. I have seen nuclear medicine evolve over the years, but I have also seen parts of the profession being taken away from us—brain imaging to CT, cardiac imaging to cardiologists, nuclear magnetic resonance (NMR) to magnetic resonance (MR), in-house radiopharmacy to unit doses. So, what about targeted therapies? I know that some oncologists are interested in bringing this into their practices. My goal is to keep this within our field of practice, and with the assistance of the Society of Nuclear Medicine and Molecular Imaging and our Molecular Therapy Task Force, we will. If you have any thoughts on this matter, you are welcome to contact me at mhcrosthwait{at}vcu.edu.

REFERENCES

  1. 1.↵
    1. Barber TW,
    2. Singh A,
    3. Kulkarni HR,
    4. et al.
    Clinical outcomes of 177lu-psma radioligand therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy. J Nucl Med. 2019;60:955–962.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Balla S,
    2. Yadav M,
    3. Bal C
    . Early results of 225Ac-DOTATATE targeted alpha therapy in metastatic gastroenteropancreatic neuroendocrine tumors: first clinical experience on safety and efficacy. J Nucl Med. 2019;60(suppl 1):74.
    OpenUrl
  3. 3.↵
    1. Bruchertseifer F,
    2. Kratochwil C,
    3. Rathke H,
    4. et al.
    Optimizing the treatment regimen for targeted alpha therapy of mCRPC with 225Ac-PSMA-617. J Nucl Med. 2019; 60(suppl 1):466.
    OpenUrl
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 47 (3)
Journal of Nuclear Medicine Technology
Vol. 47, Issue 3
September 1, 2019
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Molecular Therapy: A New Focus for SNMMI-TS
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
Molecular Therapy: A New Focus for SNMMI-TS
Mark H. Crosthwaite
Journal of Nuclear Medicine Technology Sep 2019, 47 (3) 8A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Molecular Therapy: A New Focus for SNMMI-TS
Mark H. Crosthwaite
Journal of Nuclear Medicine Technology Sep 2019, 47 (3) 8A;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Building a Stronger Workforce: SNMMI-TS Progress and Partnerships
  • Empowering the Future of Nuclear Medicine: Advancing Education, Workforce Development, and Patient Care
  • No Longer the Hidden Gem of Radiology
Show more Message from the President

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire